ACS 2010
Recent articles
Uncharted territory
Drug companies have been curiously reluctant to dive into research on therapies for autism. The chief of Pfizer's new autism research unit explains why.
Uncharted territory
Drug companies have been curiously reluctant to dive into research on therapies for autism. The chief of Pfizer's new autism research unit explains why.
True blood
Early data suggest that it is possible to identify autism by looking at gene expression in the blood. But it’s going to take more work to prove it.
True blood
Early data suggest that it is possible to identify autism by looking at gene expression in the blood. But it’s going to take more work to prove it.
Database groups common concepts in autism tests
A searchable new database will greatly ease the task of comparing results from more than 25 diagnostic tests for autism, by creating clusters of the various symptoms measured.
Database groups common concepts in autism tests
A searchable new database will greatly ease the task of comparing results from more than 25 diagnostic tests for autism, by creating clusters of the various symptoms measured.
Explore more from The Transmitter
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.